𝔖 Bobbio Scriptorium
✦   LIBER   ✦

1–42 A Randomized Trial of Exemestane After Two to Three Years of Tamoxifen Therapy in Postmenopausal Women With Primary Breast Cancer

✍ Scribed by Buzdar, A.U.

Book ID
122406346
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
64 KB
Volume
16
Category
Article
ISSN
1043-321X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Switching to exemestane after 2–3 years
Switching to exemestane after 2–3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen: Abstracted from: Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–92.
✍ Christina Davies 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 248 KB
Cost-effectiveness of switching to exeme
Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer
✍ Nancy A. Risebrough; Shailendra Verma; Maureen Trudeau; Nicole Mittmann 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views

## Abstract ## BACKGROUND. Sequential tamoxifen/exemestane therapy reportedly improves disease‐free survival in women with primary breast cancer compared with continued tamoxifen therapy. The objective of the current study was to assess the cost‐effectiveness of switching to exemestane after 2 to